Results 201 to 210 of about 575,334 (316)
Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure
Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug‐induced liver injury in a 61‐year‐old woman following 2 months of fexuprazan therapy.
Sook Jin Seong +5 more
wiley +1 more source
Healthcare trainees' Hepatitis B surface antibodies in the times of universal vaccination: a cross-sectional study. [PDF]
Ortiz-Lopez CI +6 more
europepmc +1 more source
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Is health, growth and development impaired in children who are Hepatitis B-exposed but uninfected? [PDF]
Lumley SF +3 more
europepmc +1 more source
Harvesting AAV by tangential flow filtration using reverse asymmetric membranes
Abstract Efficient bioreactor clarification for harvesting virus particles is often challenging. Tangential flow filtration is attractive as it can be easily adapted for batch and perfusion operations. Here the feasibility of using reverse asymmetric hollow fiber membranes, where the more open support structure faces the feed stream, has been ...
Xiaolei Hao +5 more
wiley +1 more source
Closing the hepatitis B birth-dose gap in Cameroon: Global evidence and policy imperatives. [PDF]
Akem TE.
europepmc +1 more source
Hepatitis B in hemodialysis patients: Significance of HBeAg
Denis J. Miller +5 more
openalex +1 more source
Abstract Background Metabolic dysfunction‐associated steatohepatitis (MASH) is anticipated to become the leading cause of hepatocellular carcinoma (HCC). Accumulating evidence indicates that N6‐methyladenosine (m6A)‐modified circular RNAs (circRNAs) play key roles in tumor malignant progression.
Jingbo Fu +22 more
wiley +1 more source

